Co-Diagnostics
CODX
65 hedge funds and large institutions have $19.9M invested in Co-Diagnostics in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 18 closing their positions.
24% more call options, than puts
Call options by funds: $1.94M | Put options by funds: $1.56M
0.1% less ownership
Funds ownership: 0.71% → 0.61% (-0.1%)
6% less funds holding
Funds holding: 69 → 65 (-4)
22% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 18
28% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 18
51% less capital invested
Capital invested by funds: $40.6M → $19.9M (-$20.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$641K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$533K |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$391K |
| 4 |
D.E. Shaw & Co
New York
|
+$381K |
| 5 |
TC
TownSquare Capital
Provo,
Utah
|
+$313K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.95M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.34M |
| 3 |
GC
Globeflex Capital
San Diego,
California
|
-$1.24M |
| 4 |
SIM
SummerHaven Investment Management
Stamford,
Connecticut
|
-$644K |
| 5 |
Morgan Stanley
New York
|
-$588K |
CODX Hedge Fund Activity: Q3 2022 in Review
65 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q3 2022, worth a combined $19.9M — down 51% from $40.6M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CODX and 14 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 13 added.
The largest buyer was Walleye Capital, opening a new position worth an estimated $641K. The largest seller was Vanguard Group, cutting an estimated $1.95M.
- 65 institutional investors held Co-Diagnostics (CODX) as of Q3 2022, down from 69 in Q2 2022.
- Funds reported $19.9M of Co-Diagnostics stock for Q3 2022, down 51% quarter-over-quarter.
- 14 funds opened new Co-Diagnostics positions in Q3 2022 and 18 closed out, a net change of -4 holders.
- The largest Co-Diagnostics buyer in Q3 2022 was Walleye Capital, an estimated $641K added.
- The largest Co-Diagnostics seller in Q3 2022 was Vanguard Group, an estimated $1.95M sold.
Based on aggregated 13F filings for Q3 2022.